Trial Profile
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Gallium 68 NeoBOMB1 (Primary) ; Gallium 68 PSMA R2 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 09 Jan 2024 Interventional study model changed from parallel to crossover.
- 09 Jan 2024 Status changed from active, no longer recruiting to completed.
- 24 May 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.